Literature DB >> 21232023

Meeting report from the 7th International Melanoma Congress, Sydney, November, 2010.

P Hersey1, K S M Smalley, A Weeraratna, M Bosenberg, X D Zhang, N K Haass, E Paton, G Mann, R A Scolyer, T Tüting.   

Abstract

The 2010 7th International Melanoma Congress sponsored by the Society for Melanoma Research and held in Sydney, Australia, was held together with the International Melanoma and Skin Cancer Centers group and the International Melanoma Pathology Study Group. As a consequence, there were over 900 registrants that included a wide range of clinicians (surgeons, medical oncologists, dermatologists) specialising in the management of melanoma as well as scientists and students carrying out laboratory-based research in melanoma. There was a general consensus that this grouping of clinicians, pathologists and scientists was mutually advantageous and plans are afoot to continue this grouping in future meetings. The meeting was dominated by the advances being made in treatment of melanoma with selective BRAF inhibitors but interest in epithelial mesenchymal transition and phenotypic changes in melanoma was apparent in many of the talks. The authors have attempted to capture many of the new developments in melanoma research but apologize to those speakers and poster presenters who had equally important findings not captured in these summaries.
© 2010 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21232023     DOI: 10.1111/j.1755-148X.2010.00811.x

Source DB:  PubMed          Journal:  Pigment Cell Melanoma Res        ISSN: 1755-1471            Impact factor:   4.693


  9 in total

Review 1.  Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma.

Authors:  Inna V Fedorenko; Kim H T Paraiso; Keiran S M Smalley
Journal:  Biochem Pharmacol       Date:  2011-05-25       Impact factor: 5.858

2.  The potential for BRAF V600 inhibitors in advanced cutaneous melanoma: rationale and latest evidence.

Authors:  Charlotte Lemech; Jeffrey Infante; Hendrik-Tobias Arkenau
Journal:  Ther Adv Med Oncol       Date:  2012-03       Impact factor: 8.168

Review 3.  Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies.

Authors:  Ragini Kudchadkar; Kim H T Paraiso; Keiran S M Smalley
Journal:  Cancer J       Date:  2012 Mar-Apr       Impact factor: 3.360

4.  BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice.

Authors:  Chengwen Liu; Weiyi Peng; Chunyu Xu; Yanyan Lou; Minying Zhang; Jennifer A Wargo; Jie Qing Chen; Haiyan S Li; Stephanie S Watowich; Yan Yang; Dennie Tompers Frederick; Zachary A Cooper; Rina M Mbofung; Mayra Whittington; Keith T Flaherty; Scott E Woodman; Michael A Davies; Laszlo G Radvanyi; Willem W Overwijk; Gregory Lizée; Patrick Hwu
Journal:  Clin Cancer Res       Date:  2012-11-30       Impact factor: 12.531

5.  Novel treatments for metastatic cutaneous melanoma and the management of emergent toxicities.

Authors:  Charlotte Lemech; Hendrik-Tobias Arkenau
Journal:  Clin Med Insights Oncol       Date:  2012-01-05

Review 6.  Using quantitative proteomic analysis to understand genotype specific intrinsic drug resistance in melanoma.

Authors:  John M Koomen; Keiran S M Smalley
Journal:  Oncotarget       Date:  2011-04

7.  What is new in the treatment of advanced melanoma? State of the art.

Authors:  Jacek Mackiewicz
Journal:  Contemp Oncol (Pozn)       Date:  2012-11-20

8.  ERBB3 is required for metastasis formation of melanoma cells.

Authors:  S Tiwary; M Preziosi; P G Rothberg; N Zeitouni; N Corson; L Xu
Journal:  Oncogenesis       Date:  2014-07-07       Impact factor: 7.485

9.  FRIZZLED7 Is Required for Tumor Initiation and Metastatic Growth of Melanoma Cells.

Authors:  Shweta Tiwary; Lei Xu
Journal:  PLoS One       Date:  2016-01-25       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.